(Q38401954)

2 September 2017

1 reference

title

Vaccines against influenza A viruses in poultry and swine: Status and future developments (English)

1 reference

2 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

J Rahn

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

D Hoffmann

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

M Beer

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

31 March 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

2414-2424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

Swine influenza viruses a North American perspective.

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Prevalence and risk factors for swine influenza virus infection in the English pig population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A review of avian influenza in different bird species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Host species barriers to influenza virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Avian and swine influenza viruses: our current understanding of the zoonotic risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Integrating surveillance and biosecurity activities to achieve efficiencies in national avian influenza programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Impact of vaccines and vaccination on global control of avian influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Biosecurity measures for backyard poultry in developing countries: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

The cost-benefit of biosecurity measures on infectious diseases in the Egyptian household poultry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Assessment of biosecurity practices of small-scale broiler producers in central Egypt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Use of vaccination in avian influenza control and eradication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Intervention strategies to reduce the risk of zoonotic infection with avian influenza viruses: scientific basis, challenges and knowledge gaps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Avian and pandemic human influenza policy in South-East Asia: the interface between economic and public health imperatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Assessment of national strategies for control of high-pathogenicity avian influenza and low-pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Experiences with vaccination in countries endemically infected with highly pathogenic avian influenza: the Food and Agriculture Organization perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

International regulations and standards for avian influenza, including the vaccine standards of the World Organisation for Animal Health.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Longitudinal 2 years field study of conventional vaccination against highly pathogenic avian influenza H5N1 in layer hens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Economic analysis of HPAI control in the Netherlands I: epidemiological modelling to support economic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Silent spread of H5N1 in vaccinated poultry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against a heterologous clade 2.2.1 Egyptian isolate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Paradox of vaccination: is vaccination really effective against avian flu epidemics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Efficacy of avian influenza vaccine in poultry: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Long-term evolution and transmission dynamics of swine influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Expanded cocirculation of stable subtypes, emerging lineages, and new sporadic reassortants of porcine influenza viruses in swine populations in Northwest Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DIVA vaccination strategies for avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Messenger RNA-based vaccines: progress, challenges, applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vector design for optimal protein expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Synthetic mRNAs with superior translation and stability properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cell engineering with synthetic messenger RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

In vitro transcription of modified RNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Selection of a T7 promoter mutant with enhanced in vitro activity by a novel multi-copy bead display approach for in vitro evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Long-term storage of DNA-free RNA for use in vaccine studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

An accessory to the 'Trinity': SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Particle size and activation threshold: a new dimension of danger signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Nucleic acid recognition by the innate immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

mRNA is an endogenous ligand for Toll-like receptor 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Direct gene transfer into mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Antiviral antibody responses: the two extremes of a wide spectrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccines: an historical perspective and view to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cationic microparticles: A potent delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cross-reactive protection against influenza A virus by a topically applied DNA vaccine encoding M gene with adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

The effect of eukaryotic expression vectors and adjuvants on DNA vaccines in chickens using an avian influenza model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunization of pigs against influenza virus infection by DNA vaccine priming followed by killed-virus vaccine boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Antibody and T cell responses induced in chickens immunized with avian influenza virus N1 and NP DNA vaccine with chicken IL-15 and IL-18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Co-administration of avian influenza virus H5 plasmid DNA with chicken IL-15 and IL-18 enhanced chickens immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of H7 subtype avian influenza DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccine development for protecting swine against influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccines and their applications in veterinary practice: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

RNA replicons - a new approach for influenza virus immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Alphavirus vectors and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Rapid development of an efficacious swine vaccine for novel H1N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Alphavirus replicon vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: proof of concept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Haemagglutinin and nucleoprotein replicon particle vaccination of swine protects against the pandemic H1N1 2009 virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

FluBlok, a next generation influenza vaccine manufactured in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunization with plant-expressed hemagglutinin protects chickens from lethal highly pathogenic avian influenza virus H5N1 challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus-like particle vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Plasmid-driven formation of influenza virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Overcoming maternal antibody interference by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of swine influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunization of pigs with an attenuated pseudorabies virus recombinant expressing the haemagglutinin of pandemic swine origin H1N1 influenza A virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Swine influenza vaccines: current status and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Success factors for avian influenza vaccine use in poultry and potential impact at the wild bird-agricultural interface.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Recombinant equine herpesvirus 1 (EHV-1) vaccine protects pigs against challenge with influenza A(H1N1)pmd09.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Recombinant Paramyxovirus Type 1-Avian Influenza-H7 Virus as a Vaccine for Protection of Chickens Against Influenza and Newcastle Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Potency of a recombinant NDV-H5 vaccine against various HPAI H5N1 virus challenges in SPF chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Deletion of the non-essential UL0 gene of infectious laryngotracheitis (ILT) virus leads to attenuation in chickens, and UL0 mutants expressing influenza virus haemagglutinin (H7) protect against ILT and fowl plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Chimeric newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Recombinant Newcastle disease virus as a vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the hemagglutinin (H5) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective immunity against avian influenza induced by a fowlpox virus recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Highly pathogenic avian influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Development and use of fowlpox vectored vaccines for avian influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

An Update on Avian Influenza in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Current Status of Veterinary Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

An elastase-dependent attenuated heterologous swine influenza virus protects against pandemic H1N1 2009 influenza challenge in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Modifications in the polymerase genes of a swine-like triple-reassortant influenza virus to generate live attenuated vaccines against 2009 pandemic H1N1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective efficacy of intranasally administered bivalent live influenza vaccine and immunological mechanisms underlying the protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A model for early onset of protection against lethal challenge with highly pathogenic H5N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

An eight-segment swine influenza virus harboring H1 and H3 hemagglutinins is attenuated and protective against H1N1 and H3N2 subtypes in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

The prospects and challenges of universal vaccines for influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Antibody recognition of a highly conserved influenza virus epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cross-neutralization of influenza A viruses mediated by a single antibody loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A common solution to group 2 influenza virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A highly conserved neutralizing epitope on group 2 influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Influenza A virus hemagglutinin protein subunit vaccine elicits vaccine-associated enhanced respiratory disease in pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Skeletal muscle cells: from local inflammatory response to active immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Skin immune sentinels in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Needle-free influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Vaccination against equine influenza: quid novi?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

From plasmids to protection: a review of DNA vaccines against infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Use of viral vectors for the development of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.052

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.03.052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25835575%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference